semaglutide 2.4 mg obesity 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Semaglutide 2.4 mg for the

Long-Term Management of Digestive Side Effects with GLP-1 Successfully managing digestive side effects, including sulphur burps, is crucial for maintaining adherence to GLP-1 therapy and achieving optimal treatment outcomes

CAUTION: Do not exceed suggested use

A study performed by Wang Z [35] found that when comparing diets where the main protein source was red meat, white meat and non-meat protein sources, consumption of red meat increased the production of TMAO, whereas white meat and non-meat protein diets generated only low to negligible amounts TMAO

In December 2024, the FDA announced that the tirzepatide shortage was resolved

Always follow your healthcare provider's instructions for dosage and frequency